How Intragenic Complementation May Unlock Genetic Therapies
2 minutes read
Scientists have discovered a rare genetic phenomenon called intragenic complementation, which could have significant implications for gene therapy and understanding diseases. This process occurs when two different mutated versions of the same gene, each of which cannot function on its own, actually restore function when present together in the same cell.
Researchers at the University of Michigan studied this effect in the gene that codes for an enzyme called argininosuccinate lyase (ASL), vital for breaking down ammonia in the body. They found that when two specific nonfunctioning mutations of the ASL gene were combined, the resulting enzyme regained its activity, essentially “complementing” each other’s defects.
This discovery matters because it suggests new ways to treat certain genetic diseases. Instead of replacing a faulty gene, therapies might introduce a second, compatible mutation to restore normal function. Understanding intragenic complementation could also help explain why some people with the same genetic disorder have very different symptoms.
We publish practical informational articles based on publicly available sources, summarizing key ideas, explanations, and useful context to help readers quickly understand a topic. Each article is reviewed prior to publication to improve clarity, accuracy, and usefulness.